ERBB2 and non-small cell lung carcinoma: According to the National Comprehensive Cancer Network (NCCN) guidelines for NSCLC, first‐line treatment for HER2‐mutant NSCLC patients is still recommended to follow the approach used for those without driver gene mutations.22